Life Sciences

Big Pharma invests in biotechnology innovation

由编辑团队,化学知识集线器金宝搏188存款

主要的药品跨国公司继续寻找新的产品开发机会,并最近投资中小型生物技术,以增强其创新治疗剂的投资组合。

Big Pharma最近采取的提高其治疗产品投资组合的一个很好的例子是Pfizer,Inc,它一直在生物技术创新上投资:在去年下半年,该公司在四个中投资了1.2亿美元临床阶段生物技术公司作为其一部分Pfizer Breakthrough Growth Initiative. Through PBGI, Pfizer is investing up to $500 million in biotechnology companies, providing funding and access to its scientific expertise to help ensure the continuity of promising clinical development programmes it says are of potential future strategic interest.

股权投资

成立于2020年6月,PBGI关注非controlling equity investments primarily in public companies with small- to medium-sized market capitalizations and in mature private companies that are developing clinical-stage assets aligned with Pfizer’s core areas of focus: Internal Medicine, Inflammation & Immunology, Oncology, Rare Disease, Vaccines, and Hospital. In addition to equity, Pfizer looks to strengthen its collaborations through participation on company and scientific advisory boards, as well as securing certain strategic rights when of mutual fit.

The initial PBGI investments include: $10 million in Vancouver, BC-based ESSA Pharma, a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer; $25 million in Cambridge, MA-based Trillium Therapeutics, a clinical-stage immuno-oncology company focused on developing innovative therapies for the treatment of cancer; $25 million in Cambridge, MA-based Vedanta Biosciences, a clinical-stage company focused on developing a new category of therapies for immune-mediated diseases based on rationally defined consortia of human-derived bacteria; and $60 million in Bedford, MA-based Homology Medicines, a clinical-stage genetic medicines company focused on treatments for rare genetic diseases with significant unmet medical needs.

Collaboration on African genetic diversity

Novartis and GSK have launched a collaboration to support high-quality scientific research investigating the link between genetic diversity across different regions in Africa and its potential impact on response to drug therapeutics. The Project Africa Genomic Research Approach for Diversity and Optimizing Therapeutics (GRADIENT), with a combined funding commitment of $3.6 million over five years, calls on African researchers to submit robust research proposals on the relevance of African genetic diversity to the treatment of malaria and tuberculosis.

Project Africa GRADIENT comprises three funding mechanisms to support the following: A limited number of fellowships in academic institutions with a reputation for global excellence to collect and analyze data on determinants of drug response; investigator-sponsored hypothesis-driven research focused on understanding genetic regional variation in drug response; and a limited number of seed-funded projects to enable the exploration of new research goals, depending on the progress made in awarding fellowships and initiating sponsored research projects.

在协议范围内,南非医学研究委员会(SAMRC)将管理该项目,联合指导委员会将监督提交的提案的审查。将优先考虑旨在从当前代表性不足的地区收集数据并改善不一致数据的科学鲁棒性的研究。计划在公共数据库中释放整理的所有数据集,以促进理解整个非洲大陆患者治疗疗效和安全性变化的方法的积极变化。

作为第一步,邀请了大学,科学委员会和其他非洲的其他公共研究组织的研究人员,以表达他们的“意图”通过SAMRC website(www.samrc.ac.za) and the final award recipients are expected to be announced by end of this year.

Merck & Co acquires clinical-stage biotechs

Merck & Co recently acquired all the outstanding shares of biotech company OncoImmune for an upfront payment of $425 million. OncoImmune recently announced positive top-line findings from an interim efficacy analysis of a Phase 3 study evaluating its lead therapeutic candidate CD24Fc for the treatment of patients with severe and critical COVID-19 and has also acquired all the outstanding shares of VelosBio for $2.75 billion in cash. VelosBio is a privately held clinical-stage biopharmaceutical company developing cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) with lead investigational candidate, VLS-101, an antibody-drug conjugate (ADC) targeting ROR1 currently being evaluated in a Phase 1 and a Phase 2 clinical trial for the treatment of patients with hematologic malignancies and solid tumours, respectively.

In October 2020, VelosBio announced the initiation of a Phase 2 clinical trial (NCT04504916) to evaluate VLS-101 for the treatment of patients with solid tumours, including patients with triple-negative breast cancer (TNBC), hormone receptor-positive and/or HER2-positive breast cancer, and non-squamous non-small-cell lung cancer (NSCLC). VLS-101 demonstrated a manageable safety profile and early signs of anti-tumour activity In early clinical trials. A Phase 1 clinical trial showed that VLS-101 resulted in objective clinical responses, including complete responses, in 47% of patients with mantle cell lymphoma (MCL) and 80% of patients with diffuse large B-cell lymphoma. VelosBio is also developing a preclinical pipeline of next-generation ADCs and bispecific antibodies targeting ROR1 with the potential to complement VLS-101 by offering alternative methods of tumour cell killing.

GSK invests in Adrestia Therapeutics

英国布伦特福德GSK House:该公司正在投资创新的生物技术,以开发新的治疗学。

In December of last year, GSK and Ahren Innovation Capital announced a Series A investment in Adrestia Therapeutics, a UK-based biotechnology company using cutting-edge molecular biology to develop precision medicines. In addition, GSK is entering into a multi-year agreement with Adrestia on up to five strategic collaborative projects, with Adrestia eligible to receive up to $230 million (£172 million) from each project in post-option milestone payments, plus royalties, subject to development and commercialization progress, across multiple arising products. In addition to the Series A investment for an equity stake, GSK is also making an upfront payment for the collaborative projects. The collaboration will combine Adrestia’s synthetic viability platform with GSK’s scientific expertise in human genetics, functional genomics, screening, and bioinformatics.

Investigational gene therapy

去年12月,詹森制药acquired the rights to Hemera Biosciences’ investigational gene therapy HMR59 for the treatment of geographic atrophy, a late-stage and severe form of age-related macular degeneration (AMD). Patients with AMD often have low levels of CD59, a protein that protects the retina from damage caused by an essential part of the body’s natural immune response called ‘complement’.

ThePhase 1 studyof HMR59 for patients with geographic atrophy has been completed and a second Phase 1 study exploring HMR59 in patients with wet-AMD is currently conducting follow-up visits to evaluate long-term safety.

Difficult-to-drug targets

伊利诺伊州芝加哥的雅培实验室的PHRMA/本地内容项目。凯文·J·宫崎骏/雷德克斯的静态照片

AbbVie and Frontier Medicines Corporation, a precision medicine company drugging challenging protein targets to develop new medicines, have established a global strategic collaboration to discover, develop and commercialize a pipeline of innovative small-molecule therapeutics against high-interest, difficult-to-drug protein targets. The two companies are utilizing Frontier’s proprietary chemoproteomics platform to identify small molecules for programmes directed to novel E3 ligases and certain oncology and immunology targets. The companies say that by selecting certain immunology and oncology targets that are considered well validated but, so far, inaccessible, the collaboration has the potential to develop highly differentiated and efficacious therapeutics.

Abbvie将向Frontier支付5500万美元的前期现金付款。Frontier有资格获得额外的里程碑付款,Abbvie将通过临床前开发的阶段来报销Frontier的研发成本。两家公司将在针对E3连接酶,免疫学和肿瘤学目标的计划的研究和临床前开发进行合作,并在成功完成临床前开发的定义阶段后,Abbvie将对这些计划的全球发展和商业化活动和成本承担全部责任,而这些计划的成本和成本是在同时承担的。在第二阶段临床开发之前,Frontier将保留某些肿瘤学计划的开发活动和费用的选择。

Frontier will be eligible to receive success-based development and commercial milestone payments that could potentially exceed $1 billion in addition to royalty payments on commercialized products and AbbVie retains the right to expand the collaboration in the future by exercising options to a defined number of additional targets. The collaboration excludes all of Frontier’s internal programmes for which the company retains its exclusive global rights.

Sanofi续约谁合作

赛诺菲(Sanofi)已重新与世卫组织(Who)疏忽了其被忽视的热带疾病合作伙伴关系,合并了20年的合作,以开发针对某些最被忽视的热带疾病的治疗方法,并支持世界卫生组织在2030年之前消除这项新的五年的卧铺疾病。承诺,赛诺菲将提供一致的财政支持,并提供2500万美元(每年500万美元),专门用于疾病管理,包括筛查人口,疾病宣传运动,能力建设和药物捐赠。

赛诺菲(Sanofi)与世界卫生组织(WHO)于2001年开始的伙伴关系是为了支持筛查,控制和治疗《睡病》,这是影响最不受欢迎的撒哈拉以南非洲国家人群的最被忽视的热带疾病之一。自2001年以来,已有超过4000万人因睡眠疾病而被筛查,并且已经进行了21万名患者的治疗和保存。在20年中,这种疾病的病例数(如果没有治疗)减少了97%。自2006年以来,赛诺菲与世卫组织的合作也已扩展,包括三种其他疾病:利什曼病,夏加斯病和伯利里溃疡。

更多的信息

有关本文中有关公司的更多信息,请参见以下网站:

www.pfizer.com

www.novartis.com

www.gsk.com

www.merck.com

www.janssen.com

www.abbvie.com

www.sanofi.com